Alvion Pharmaceuticals SMSA
Alvion Pharmaceuticals is a privately held Greek pharmaceutical company that develops non-infringing, complex generic medicines and out-licenses them to 90+ pharmaceutical partners across 40+ countries in Europe, MENA, Canada, Australia, South Africa, Latin America and Southeast Asia.
- Company typePrivate
- Founded2020
- HeadquartersAthens, Greece
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Alvion Pharmaceuticals SMSA does
Alvion Pharmaceuticals SMSA is a privately held, science-oriented pharmaceutical company headquartered in Athens, Greece (Pallini, Attika), with regional offices in Galway, Ireland and Durban, South Africa. The company develops and manufactures non-infringing generic medicines — focusing on difficult-to-formulate products such as extended-release and fixed-combination formulations — often backed by formulation patents. Its core commercialized assets include Ticagrelor film coated tablets (a generic equivalent to Brilique, for prevention of major adverse cardiac events) and Mirabegron Prolonged Release tablets (a generic equivalent to MYRBETRIQ for overactive bladder), with EU eCTD dossiers and DCP filings in progress or completed for European market entry.
The company operates an asset-light, B2B out-licensing and supply model: Alvion develops formulations, secures regulatory dossiers and formulation IP, and licenses finished products or supply rights to 90+ pharmaceutical companies across 40+ countries spanning Europe, MENA, Canada, Australia, South Africa, Latin America and Southeast Asia. Revenue is generated through licensing royalties and one-time license/supply agreements. The company is described as an IP powerhouse providing licensing rights to the largest pharmaceutical companies globally.
Alvion's strategic positioning is to be first-to-market at or before patent expiry by developing non-infringing formulations that sidestep originator patents. It pursues this via co-development partnerships (notably V-Ensure Pharma Technologies for complex generics) and regional distribution agreements (notably Lupin Limited for Southeast Asia). In April 2026, the company received a strategic investment from iGrow Venture Partners VC, earmarked for R&D acceleration and global footprint expansion. Leadership comprises John Bouros as CEO and Marina Ioannidou as Corporate Communications Head; the company employs 11-50 staff and remains privately held with no public revenue disclosure.
Alvion Pharmaceuticals SMSA firmographics
Firmographics- Name
- Alvion Pharmaceuticals SMSA
- Legal name
- Alvion Pharmaceuticals Single Member S.A.
- Website
- https://alvionpharma.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Alvion Pharmaceuticals is a privately held Greek pharmaceutical company that develops non-infringing, complex generic medicines and out-licenses them to 90+ pharmaceutical partners across 40+ countries in Europe, MENA, Canada, Australia, South Africa, Latin America and Southeast Asia.
- Ownership category
- akta.pro rank
Alvion Pharmaceuticals SMSA industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Complex Generics (e.g., inhalation, transdermal, liposomal) (HLAIABAB)
- akta.pro secondary industry
- Oral Solid Dose (OSD) Generics (HLAIABAD)
Keywords
Where Alvion Pharmaceuticals SMSA is headquartered
LocationHeadquarters
- HQ city
- Athens
- HQ country
- Greece
- HQ region
- Europe
Offices3 records
Markets served
Alvion Pharmaceuticals SMSA business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Others
Revenue model
- Out-licensing of proprietary products: Alvion develops and licenses its proprietary generic medicines to leading pharmaceutical companies. Out-licensing of proprietaries and supplying these medicines is the core business of the group.
- Supply agreements: Supply of manufactured medicines to pharmaceutical partners via both proprietary and supply licensing agreements
Go-to-market motion1 record
Distribution channels2 records
Marketing channels2 records
Alvion Pharmaceuticals SMSA product offering
Product offeringCore offering
Alvion develops and manufactures non-infringing generic medicines, including Ticagrelor film coated tablets and Mirabegron Prolonged Release tablets, and out-licenses these proprietary formulations to leading pharmaceutical companies worldwide. The company focuses on difficult-to-develop generics with proprietary formulation technologies, often patented, and operates through B2B licensing and supply agreements across 40+ countries.
Product overview
Alvion Pharmaceuticals is a science-oriented pharmaceutical company that develops and manufactures non-infringing generic medicines in Europe. The company operates as a vertically integrated pharmaceutical organization offering a portfolio of added-value generic medicines across therapeutic categories including cardiovascular, diabetes, urinary, and central nervous system. The core products include Ticagrelor Film Coated Tablets (cardiovascular) and Mirabegron PR Tablets (urinary/overactive bladder), which are out-licensed to leading pharmaceutical companies worldwide. Alvion focuses on difficult-to-develop products using non-infringing formulations, often backed by formulation patents, with emphasis on fixed combination technologies and extended-release formulations.
Differentiator
Problem solved
Functional benefit
Products and services
- Ticagrelor Film Coated Tablets Generic medicine equivalent to Brilique (AstraZeneca), used for prevention of stroke, heart attack and other events in patients with acute coronary syndrome; reduces risk of major adverse cardiac events (MACE) in myocardial infarction patients. Out-licensed to pharmaceutical partners across multiple regions.
- Mirabegron PR (Prolonged Release) Tablets Generic medicine equivalent to MYRBETRIQ (Astellas), indicated for treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency. Available in 25mg and 50mg strengths and protected by proprietary non-infringing formulation patents.
Quantifiable outcome
- Delivering medicines to millions of patients globally
Companies that use Alvion Pharmaceuticals SMSA
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles1 record
Alvion Pharmaceuticals SMSA technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Alvion Pharmaceuticals SMSA partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered major and core.
- Lupin LimitedmajorLicensing agreement for commercialization of cardiometabolic medicines in Southeast Asia region (Malaysia, Vietnam). Lupin committed to providing new affordable treatment options and expanding footprint in the region with quality cost-effective alternatives.
- V-Ensure Pharma TechnologiescoreCo-development partner for complex generics formulations including Mirabegron Prolonged Release. V-Ensure is a fully integrated specialty pharma company with proprietary technology platforms and established R&D track record with successful delivery of over 150 formulations.
Scale indicators4 records
Recent moves5 records
Expansion highlights5 records
Alvion Pharmaceuticals SMSA competitors and assessment
Company assessmentDirect peers
- Stada Arzneimittel: Stada is a European-focused generics and consumer health company with broad portfolio coverage across cardiovascular, urology and CNS. It shares Alvion's model of out-licensing and regional distribution partnerships across Europe and emerging markets.
- Lupin Limited: Lupin is a major Indian-headquartered global generics and specialty pharma company and an existing licensing partner of Alvion for Southeast Asia. Both companies commercialize complex generics via out-licensing and regional distribution agreements, making Lupin a directly comparable generics player and channel partner.
- Apotex: Apotex is one of the largest Canadian-owned generics manufacturers with global licensing reach. Its focus on complex generics and value-added formulations parallels Alvion's positioning around non-infringing and difficult-to-develop products.
- Glenmark Pharmaceuticals: Glenmark is an India-headquartered generics and specialty pharma company with licensing and distribution agreements across emerging markets. Its pipeline of complex generics and out-licensing deals in cardiovascular and CNS therapies aligns closely with Alvion's strategy.
- Polpharma: Polpharma is a Central European generics and OTC manufacturer with pan-European distribution and a portfolio of value-added generics. Its geographic concentration and licensing model across Eastern and Central Europe closely mirrors Alvion's European footprint.
Emerging players
- Alvotech: Alvotech is a focused biosimilars and complex generics developer with a licensing-led commercial model similar to Alvion's. It shares Alvion's emphasis on difficult-to-develop formulations and partnerships with major pharma companies for global reach.
Broad incumbents
- Hikma Pharmaceuticals: Hikma is a multinational generics and specialty injectable manufacturer with strong presence in MENA, Europe and the US. Its MENA and European footprint overlaps materially with Alvion's geographic focus.
- Viatris: Viatris is a global generics and specialty pharma major formed from Mylan and Upjohn. It competes with Alvion in cardiovascular and urology generics across regulated and emerging markets via an extensive global distribution network.
- Sandoz (Novartis): Sandoz is the global generics and biosimilars arm of Novartis and one of the two largest pure-play generics companies worldwide. It offers overlapping capabilities with Alvion in complex generics across European and global markets as part of a much broader portfolio.
- Teva Pharmaceutical Industries: Teva is the world's largest generics manufacturer with an extensive complex generics portfolio. It competes with Alvion across the same therapeutic areas but operates at far greater scale across R&D, manufacturing and global commercialization.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Alvion Pharmaceuticals SMSA social profiles
Digital presenceAlvion Pharmaceuticals SMSA financial estimates
Financial estimateRevenue estimate
Valuation estimate
Alvion Pharmaceuticals SMSA leadership team
Management profileNumber of profiles
Profiles2 records
Alvion Pharmaceuticals SMSA funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Alvion Pharmaceuticals SMSA M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Alvion Pharmaceuticals SMSA
What does Alvion Pharmaceuticals SMSA do?
Alvion develops and manufactures non-infringing generic medicines, including Ticagrelor film coated tablets and Mirabegron Prolonged Release tablets, and out-licenses these proprietary formulations to leading pharmaceutical companies worldwide. The company focuses on difficult-to-develop generics with proprietary formulation technologies, often patented, and operates through B2B licensing and supply agreements across 40+ countries.
Is Alvion Pharmaceuticals SMSA a public or private company?
Alvion Pharmaceuticals SMSA is a private company. It is classified as venture growth investor backed and is currently operating.
When was Alvion Pharmaceuticals SMSA founded?
Alvion Pharmaceuticals SMSA was founded in 2020. It employs 11 to 50 people.
Where is Alvion Pharmaceuticals SMSA based?
Alvion Pharmaceuticals SMSA is headquartered in Athens, Greece, in the Europe region.
How does Alvion Pharmaceuticals SMSA make money?
Two revenue lines are on record. Out-licensing of proprietary products are the primary driver. The others are supply agreements.
Who are Alvion Pharmaceuticals SMSA's main competitors?
Direct peers on record are Stada Arzneimittel, Lupin Limited, Apotex, Glenmark Pharmaceuticals and Polpharma. Alvotech is listed as an emerging player. Broad incumbents are Hikma Pharmaceuticals, Viatris, Sandoz (Novartis) and Teva Pharmaceutical Industries.
Does Alvion Pharmaceuticals SMSA have an API?
No public API is recorded for Alvion Pharmaceuticals SMSA.
What industry is Alvion Pharmaceuticals SMSA in?
Alvion Pharmaceuticals SMSA's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAB, Complex Generics (e.g., inhalation, transdermal, liposomal), with a secondary code of HLAIABAD, Oral Solid Dose (OSD) Generics. Its NAICS code is 325412 and its SIC code is 2834.